NASDAQ: AIMDAinos Inc Stock
$1.84-0.07 (-3.66%)
Updated Jun 15, 2026
AIMD Price
$1.84
Fair Value Price
N/A
Market Cap
$15.69M
52 Week Low
$1.26
52 Week High
$4.50
P/E
-0.64x
P/B
2.76x
P/S
463.33x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.11k
Earnings
-$13.94M
Gross Margin
79.2%
Operating Margin
-73,080.76%
Profit Margin
-76,996.2%
Debt to Equity
2.88
Operating Cash Flow
-$4M
Beta
0.6
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AIMD Overview
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AIMD's potential to beat the market
- AIMD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
AIMD
RankedUnranked of 94
RankedUnranked of 94
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.60 | A | |
| $37.44 | A | |
| $26.36 | A |
Be the first to know about important AIMD news, forecast changes, insider trades & much more!
AIMD News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AIMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AIMD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AIMD is good value based on its book value relative to its share price (2.76x), compared to the US Medical Devices industry average (2.97x)
P/B vs Industry Valuation
AIMD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AIMD due diligence checks available for Premium users.
Valuation
AIMD fair value
Fair Value of AIMD stock based on Discounted Cash Flow (DCF)
Price
$1.84
Fair Value
-$0.90
Undervalued by
304.75%
AIMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AIMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.64x
Industry
20.39x
Market
14.3x
AIMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.76x
Industry
2.97x
AIMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AIMD's financial health
Profit margin
Revenue
$161.0
Net Income
-$2.5M
Profit Margin
-1,527,826.1%
AIMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AIMD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$22.1M
Liabilities
$16.4M
Debt to equity
2.88
AIMD's short-term liabilities ($6.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AIMD's long-term liabilities ($10.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AIMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AIMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$983.4k
Investing
-$79.0
Financing
$3.4M
AIMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AIMD vs Medical Device Stocks
Ainos Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.